Volver a Agenda
Session Chair(s)
David Ohlssen, PHD
Senior Expert Methodologist
Novartis Pharmaceuticals Corporation, United States
Learning Objective : Interpret the intent of the FDA guidance on adaptive designs; Identify key factors required by regulators in the review of adaptive trials; Apply adaptive trials within their own clinical development programs.
Speaker(s)
FDA Viewpoint
Lisa LaVange, PHD
University of North Carolina at Chapel Hill, United States
Professor Emerita
Innovative Dose-Finding Using Novel Adaptive Design and Analysis Approaches
Silke Jörgens
ICON Plc, Germany
Senior Statistical Consultant
Adaptive Designs: An Exercise in Change Management
Vladimir Dragalin, PHD
Janssen R&D, at Johnson & Johnson, United States
Vice President, Scientific Fellow
¿Tiene una cuenta?